RxDoctor Payments Data

Arie Szatkowski, MD

Cardiovascular Disease · Memphis, TNNPI 1356443451

Payments from drug & device makers

$12,533in general payments, 2019–2025

Across 523 payments — averaging $23.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Amgen$905
  • Actelion Pharmaceuticals US, Inc.$665
  • Merck$607
  • AstraZeneca$579
  • Pfizer$556
  • plus $5K from 32 others

What the payments were for

  • Travel & lodging$1,71114%
  • Food & beverage$10,79586%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,533 in reported general payments places this provider in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$681,569
Medicare patients
2,488
Services billed
15,820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,428$1,311,245
EntrestoSacubitril/Valsartan661$683,731
JardianceEmpagliflozin593$541,732
XareltoRivaroxaban326$327,516
Repatha SureclickEvolocumab261$199,717
FarxigaDapagliflozin Propanediol116$94,452
BrilintaTicagrelor94$60,214
OzempicSemaglutide36$48,079
Praluent PenAlirocumab75$44,084
Repatha SyringeEvolocumab55$41,757
VascepaIcosapent Ethyl81$32,837
Droxidopa13$21,412
WegovySemaglutide15$21,008
MultaqDronedarone Hcl18$19,698
MounjaroTirzepatide14$16,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$556$1,311,2451,428 claims
NovartisEntresto$401$683,731661 claims
Boehringer IngelheimJardiance, Combivent Respimat$219$549,549607 claims
Johnson & JohnsonXarelto$354$327,516326 claims
AstraZenecaFarxiga, Brilinta$579$154,666210 claims
Novo NordiskOzempic, Wegovy$285$69,08751 claims
Sanofi-aventis U.S. LLCMultaq$274$19,69818 claims
MerckVerquvo$607$7,56712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →